‘Exciting’ brepocitinib data may open door for first targeted dermatomyositis drug

Treatment with once-daily brepocitinib improved skin disease, muscle and physical function measures for adults with dermatomyositis while minimizing steroid burden, with benefits as early as 4 weeks and sustained for 1 year, data show.Findings from the phase 3 VALOR study assessing brepocitinib (Priovant Therapeutics), an oral dual selective tyrosine kinase (TYK) 2 and JAK 1 inhibitor, were